- Undeterred by its solanezumab flop, Eli Lilly (NYSE:LLY) inks an agreement with AstraZeneca (AZN) to co-develop MEDI1814, an antibody selective for amyloid beta 42 currently in Phase 1 development. The deal builds on the companies' existing collaboration related to BACE inhibitor AZD3293, in Phase 3 development.
- Under the terms of the agreement, Lilly will pay an upfront fee of $30M to AstraZeneca. Other financial terms are not disclosed.
- Amyloid beta is type of protein that leads to the formation of amyloid plaques in the brain, the accumulation of which is associated with Alzheimer's disease (AD) . Amyloid beta 42 is a form of amyloid beta that is particularly associated with AD.
-
MEDI1814 was originally developed at MedImmune which AstraZeneca acquired for $15.6B in 2007.